OncoPrism
Commercial- Indications
- Multiple solid tumors
Company intelligence / Profile preview
Cofactor Genomics has developed OncoPrism™, an RNA-based diagnostic that predicts patient responses to immunotherapies by analyzing the immune microenvironment of tumors. The technology uses machine learning to interpret multidimensional RNA biomarkers from pre-treatment biopsies. The PREDAPT trial, involving over two dozen healthcare systems, evaluates its utility across multiple solid tumor types. Early results show promise for improving precision medicine by better matching patients with effective therapies.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cofactor Genomics.